3rdPartyFeeds

Weekly Cannabis Stock News: Scotts Miracle-Gro Keeps Growing, Cronos Buys Lord Jones

The supplier to the cannabis stars posts strong quarterly results, as does Aphria. Meanwhile, Cronos goes shopping at the beauty counter. Read More...

Last week landed smack in the thick of earnings season, and consequently, several companies in the marijuana sector reported their latest fundamentals. Happily, these were largely encouraging.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Outside of that, there was some dealmaking in the sector, which investors also greeted positively. So in contrast to last week, with its cannabis company CEO firings and regulatory warnings, this one was generally sunnier for marijuana stock investors.” data-reactid=”12″>Outside of that, there was some dealmaking in the sector, which investors also greeted positively. So in contrast to last week, with its cannabis company CEO firings and regulatory warnings, this one was generally sunnier for marijuana stock investors.

Marijuana leaf with sun shining behind it

Image source: Getty Images

Scotts Miracle-Gro keeps growing

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Arguably the best picks-and-shovels play among marijuana stocks, Scotts Miracle-Gro (NYSE: SMG) posted double-digit growth in key fundamentals in its latest quarter.” data-reactid=”26″>Arguably the best picks-and-shovels play among marijuana stocks, Scotts Miracle-Gro (NYSE: SMG) posted double-digit growth in key fundamentals in its latest quarter.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The gardening equipment and supplies company posted its fiscal third-quarter 2019 results. These showed that revenue grew like a wild weed, rising 18% on a year-over-year basis to just under $1.2 billion. Non-GAAP (adjusted) net income came in 17% higher at $176 million ($3.11 per share). Both figures trumped analyst estimates; on average, these were for $1.07 billion on the top line and earnings per share (EPS) of $2.74.” data-reactid=”27″>The gardening equipment and supplies company posted its fiscal third-quarter 2019 results. These showed that revenue grew like a wild weed, rising 18% on a year-over-year basis to just under $1.2 billion. Non-GAAP (adjusted) net income came in 17% higher at $176 million ($3.11 per share). Both figures trumped analyst estimates; on average, these were for $1.07 billion on the top line and earnings per share (EPS) of $2.74.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Better, as far as marijuana stock investors are concerned, the company’s Hawthorne unit — which supplies products used by cannabis growers — was a big driver of growth. The division’s organic sales during the quarter rose by 49%.” data-reactid=”28″>Better, as far as marijuana stock investors are concerned, the company’s Hawthorne unit — which supplies products used by cannabis growers — was a big driver of growth. The division’s organic sales during the quarter rose by 49%.

Finally, the company upped its full-year adjusted net profit guidance for not the first, but the second time in fiscal 2019. It now believes adjusted EPS will come in at $4.35 to $4.50, on the back of 16% to 17% sales growth.

Scotts Miracle-Gro is in the right place and right time to benefit from the sharp expansion of the cannabis growing industry. Given the dynamics of the market and the company’s solid position, its expected (and continued) double-digit growth is eminently achievable.

Aphria Q4 — surprising success

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Another marijuana stock posting on the quarterly scoreboard this week was Aphria (NYSE: APHA). The Canadian company flipped to a solid profit on the bottom line, while showing impressive revenue growth.” data-reactid=”32″>Another marijuana stock posting on the quarterly scoreboard this week was Aphria (NYSE: APHA). The Canadian company flipped to a solid profit on the bottom line, while showing impressive revenue growth.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Said revenue was up by nearly 1,000% year over year in the company’s fourth quarter of fiscal 2019, to CA$129 million. Net profit was nearly CA$16 million, which shook out to CA$0.05 per share and was in vivid contrast to the Q4 2018 net loss of CA$5 million (CA$0.04). These improvements were on the back of an over four-fold rise in kilos and kilogram equivalents sold, which in the latest quarter stood at 5,574.” data-reactid=”33″>Said revenue was up by nearly 1,000% year over year in the company’s fourth quarter of fiscal 2019, to CA$129 million. Net profit was nearly CA$16 million, which shook out to CA$0.05 per share and was in vivid contrast to the Q4 2018 net loss of CA$5 million (CA$0.04). These improvements were on the back of an over four-fold rise in kilos and kilogram equivalents sold, which in the latest quarter stood at 5,574.

The great bulk of the revenue growth, at least, was due to its recent acquisition of CC Pharma (a German medical marijuana distributor). But the performance of that unit was baked into estimates; the fact that Aphria still exceeded expectations was very heartening. Its efforts at brand building, efficiency, and a concentration on core strengths appear to be working.

No wonder Aphria stock was an outperformer this week. From Monday to Friday, its price rose by 33%.

Cronos acquires Lord Jones CBD personal care products

This week wasn’t all about quarterly updates in the cannabis sector; there was some dealmaking, too.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Cronos Group (NASDAQ: CRON) announced it reached an agreement to buy the CBD-based skincare and beauty products line operated by Redwood Holding Group under the brand name Lord Jones.” data-reactid=”38″>Cronos Group (NASDAQ: CRON) announced it reached an agreement to buy the CBD-based skincare and beauty products line operated by Redwood Holding Group under the brand name Lord Jones.

Cronos is parting with around $300 million to buy Lord Jones. Most of this ($225 million) is to be transacted in cash, the rest to be settled in Cronos stock. The deal is expected to close some time this calendar quarter.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="As Redwood is a privately held company, we don't have a fix on how it's doing financially, and in its press release on the acquisition, Cronos didn't provide many clues. Regardless, Lord Jones has positioned itself as a premium brand, apparently with success — its products have been written up in publications such as The New York Times, and several celebrities are known to be devotees.” data-reactid=”44″>As Redwood is a privately held company, we don’t have a fix on how it’s doing financially, and in its press release on the acquisition, Cronos didn’t provide many clues. Regardless, Lord Jones has positioned itself as a premium brand, apparently with success — its products have been written up in publications such as The New York Times, and several celebrities are known to be devotees.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Besides, Cronos is one of those rare marijuana companies with a relatively high cash pile; it held CA$2.4 billion at the end of its most recently reported quarter. So the company is spending well within its means to acquire a highly complementary asset with some consumer cachet. Knowing what we know, then, this seems like a smart move for Cronos.” data-reactid=”45″>Besides, Cronos is one of those rare marijuana companies with a relatively high cash pile; it held CA$2.4 billion at the end of its most recently reported quarter. So the company is spending well within its means to acquire a highly complementary asset with some consumer cachet. Knowing what we know, then, this seems like a smart move for Cronos.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content=" More From The Motley Fool ” data-reactid=”46″> More From The Motley Fool

 

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.” data-reactid=”52″>Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="This article was originally published on Fool.com” data-reactid=”53″>This article was originally published on Fool.com

Read More

Add Comment

Click here to post a comment